Thus, in chronic kidney disease, when EPO production is restricted due to kidney damage, Hb levels are higher for higher BMI and lower EPO doses are required to maintain Hb levels in obese compared to normal weight patients [26]. Here, GSTM1 is linked to chronic kidney disease.